These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 21843305)

  • 1. Initiation of insulin glargine in patients with Type 2 diabetes in suboptimal glycaemic control positively impacts health-related quality of life. A prospective cohort study in primary care.
    Hajos TR; Pouwer F; de Grooth R; Holleman F; Twisk JW; Diamant M; Snoek FJ
    Diabet Med; 2011 Sep; 28(9):1096-102. PubMed ID: 21843305
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Initiation of insulin glargine therapy in type 2 diabetes subjects suboptimally controlled on oral antidiabetic agents: results from the AT.LANTUS trial.
    Davies M; Lavalle-González F; Storms F; Gomis R;
    Diabetes Obes Metab; 2008 May; 10(5):387-99. PubMed ID: 18355327
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does hypoglycaemia affect the improvement in QoL after the transition to insulin in people with type 2 diabetes?
    Wieringa TH; de Wit M; Twisk JWR; Snoek FJ
    J Endocrinol Invest; 2018 Feb; 41(2):249-258. PubMed ID: 28803366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transferring to insulin detemir from NPH insulin or insulin glargine in type 2 diabetes patients on basal-only therapy with oral antidiabetic drugs improves glycaemic control and reduces weight gain and risk of hypoglycaemia: 14-week follow-up data from PREDICTIVE.
    Dornhorst A; Lüddeke HJ; Koenen C; Meriläinen M; King A; Robinson A; Sreenan S;
    Diabetes Obes Metab; 2008 Jan; 10(1):75-81. PubMed ID: 18034846
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes.
    Rosenstock J; Davies M; Home PD; Larsen J; Koenen C; Schernthaner G
    Diabetologia; 2008 Mar; 51(3):408-16. PubMed ID: 18204830
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The longitudinal association between glycaemic control and health-related quality of life following insulin therapy optimisation in type 2 diabetes patients. A prospective observational study in secondary care.
    Hajos TR; Pouwer F; de Grooth R; Holleman F; Twisk JW; Diamant M; Snoek FJ
    Qual Life Res; 2012 Oct; 21(8):1359-65. PubMed ID: 22065281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glycemic control with insulin glargine plus insulin glulisine versus premixed insulin analogues in real-world practices: a cost-effectiveness study with a randomized pragmatic trial design.
    Levin PA; Zhang Q; Mersey JH; Lee FY; Bromberger LA; Bhushan M; Bhushan R
    Clin Ther; 2011 Jul; 33(7):841-50. PubMed ID: 21719107
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Initiating insulin therapy in elderly patients with Type 2 diabetes: efficacy and safety of lispro mix 25 vs. basal insulin combined with oral glucose-lowering agents.
    Wolffenbuttel BH; Klaff LJ; Bhushan R; Fahrbach JL; Jiang H; Martin S
    Diabet Med; 2009 Nov; 26(11):1147-55. PubMed ID: 19929994
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insulin glargine benefits patients with type 2 diabetes inadequately controlled on oral antidiabetic treatment: an observational study of everyday practice in 12,216 patients.
    Schreiber SA; Haak T
    Diabetes Obes Metab; 2007 Jan; 9(1):31-8. PubMed ID: 17199716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.
    Waugh N; Cummins E; Royle P; Clar C; Marien M; Richter B; Philip S
    Health Technol Assess; 2010 Jul; 14(36):1-248. PubMed ID: 20646668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insulin degludec improves health-related quality of life (SF-36® ) compared with insulin glargine in people with Type 2 diabetes starting on basal insulin: a meta-analysis of phase 3a trials.
    Freemantle N; Meneghini L; Christensen T; Wolden ML; Jendle J; Ratner R
    Diabet Med; 2013 Feb; 30(2):226-32. PubMed ID: 23199058
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparable glycaemic control and hypoglycaemia in adults with type 2 diabetes after initiating insulin glargine 300 units/mL or insulin degludec: The DELIVER Naïve D real-world study.
    Sullivan SD; Nicholls CJ; Gupta RA; Menon AA; Wu J; Westerbacka J; Bosnyak Z; Frias JP; Bailey TS
    Diabetes Obes Metab; 2019 Sep; 21(9):2123-2132. PubMed ID: 31144445
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Initiation of insulin glargine in suboptimally controlled patients with type 2 diabetes: sub-analysis of the AT.LANTUS trial comparing treatment outcomes in subjects from primary and secondary care in the UK.
    Davies M; Evans R; Storms F; Gomis R; Khunti K
    Diabetes Obes Metab; 2007 Sep; 9(5):706-13. PubMed ID: 17697063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of intensive mixture therapy with basal insulin therapy in insulin-naïve patients with type 2 diabetes receiving oral antidiabetes agents.
    Jacober SJ; Scism-Bacon JL; Zagar AJ
    Diabetes Obes Metab; 2006 Jul; 8(4):448-55. PubMed ID: 16776752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A study comparing insulin lispro mix 25 with glargine plus lispro therapy in patients with Type 2 diabetes who have inadequate glycaemic control on oral anti-hyperglycaemic medication: results of the PARADIGM study.
    Bowering K; Reed VA; Felicio JS; Landry J; Ji L; Oliveira J
    Diabet Med; 2012 Sep; 29(9):e263-72. PubMed ID: 22672081
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of initiation and titration of a single pre-prandial dose of insulin glulisine while continuing titrated insulin glargine in type 2 diabetes: a 6-month 'proof-of-concept' study.
    Owens DR; Luzio SD; Sert-Langeron C; Riddle MC
    Diabetes Obes Metab; 2011 Nov; 13(11):1020-7. PubMed ID: 21679291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Better long-term glycaemic control with the basal insulin glargine as compared with NPH in patients with Type 1 diabetes mellitus given meal-time lispro insulin.
    Porcellati F; Rossetti P; Pampanelli S; Fanelli CG; Torlone E; Scionti L; Perriello G; Bolli GB
    Diabet Med; 2004 Nov; 21(11):1213-20. PubMed ID: 15498088
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patient-directed titration for achieving glycaemic goals using a once-daily basal insulin analogue: an assessment of two different fasting plasma glucose targets - the TITRATE study.
    Blonde L; Merilainen M; Karwe V; Raskin P;
    Diabetes Obes Metab; 2009 Jun; 11(6):623-31. PubMed ID: 19515182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glargine is superior to neutral protamine Hagedorn for improving glycated haemoglobin and fasting blood glucose levels during intensive insulin therapy.
    Fulcher GR; Gilbert RE; Yue DK
    Intern Med J; 2005 Sep; 35(9):536-42. PubMed ID: 16105155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insulin glargine provides greater improvements in glycaemic control vs. intensifying lifestyle management for people with type 2 diabetes treated with OADs and 7-8% A1c levels. The TULIP study.
    Blicklé JF; Hancu N; Piletic M; Profozic V; Shestakova M; Dain MP; Jacqueminet S; Grimaldi A
    Diabetes Obes Metab; 2009 Apr; 11(4):379-86. PubMed ID: 19087105
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.